Following early suppression of glucose consumption upon treatment with the BRAF inhibitor vemurafenib, subsequent increases in glucose uptake as assessed using FDG uptake in treated tumours tightly correlated with emergence of resistance [76]. Here, BRAF is linked to neoplasm.